Cargando…

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells

Prevention of graft-versus-host disease (GVHD) is paramount for allogeneic hematopoietic stem cell transplantation (HSCT) to treat nonmalignant diseases. We previously reported that allogeneic HSCT for severe aplastic anemia (SAA) using the fludarabine, cyclophosphamide, and alemtuzumab (Campath-1H)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grimaldi, Francesco, Potter, Victoria, Perez-Abellan, Pilar, Veluchamy, John P., Atif, Muhammad, Grain, Rosemary, Sen, Monica, Best, Steven, Lea, Nicholas, Rice, Carmel, Pagliuca, Antonio, Mufti, Ghulam J., Marsh, Judith C.W., Barber, Linda D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Carden Jennings Publishing 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270460/ https://www.ncbi.nlm.nih.gov/pubmed/27816648 http://dx.doi.org/10.1016/j.bbmt.2016.11.003

Ejemplares similares

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients
por: Ramalingam, S., et al.
Publicado: (2006)

Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT)
por: Miller, Paul D. E., et al.
Publicado: (2019)

Madurella Mycetomatis Infection Following Allogenic Stem Cell Transplantation for Aplastic Anemia
por: Sharma, Sanjeev Kumar, et al.
Publicado: (2012)

SARS-CoV-2 infection in aplastic anemia
por: Avenoso, Daniele, et al.
Publicado: (2021)

Somatic mutations in aplastic anemia: Significance for classification, therapy, and outcome
por: Wood, Henry J., et al.
Publicado: (2019)

Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation
por: Wang, Jiayu, et al.
Publicado: (2022)

P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY
por: Aggarwal, N., et al.
Publicado: (2022)

Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study
por: Sheth, Vipul, et al.
Publicado: (2021)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients
por: Nguyen, Kristy, et al.
Publicado: (2022)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis
por: Rabitsch, W., et al.
Publicado: (2016)

Coexisting Pulmonary Tuberculosis and Mucormycosis in a Patient with Aplastic Anemia Post Allogenic Stem Cell Transplantation
por: Sharma, Sanjeev Kumar, et al.
Publicado: (2011)

Lichen Striatus Occurring after Allogenic Peripheral Blood Stem Cell Transplantation in an Adult with Aplastic Anemia
por: Mun, Je-Ho, et al.
Publicado: (2012)

Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single Centre Experience in Malaysia
por: Wilfred, Gilbert, et al.
Publicado: (2022)

Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
por: Qasim, Waseem
Publicado: (2023)

Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness
por: Bouvy, Anne P., et al.
Publicado: (2016)

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
por: Burns, D M, et al.
Publicado: (2016)

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E, et al.
Publicado: (2017)

Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation
por: Drexler, Beatrice, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Clones: Time for a Change
por: Gavriilaki, Eleni, et al.
Publicado: (2020)

Shifting Paradigms: The Case of Autologous Reconstitution after an Upfront Matched Unrelated Hematopoietic Cell Transplantation for Severe Acquired Aplastic Anemia in a Child
por: Pochon, Cécile, et al.
Publicado: (2023)

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2019)

Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy
por: Le Calvez, Baptiste, et al.
Publicado: (2022)

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
por: Fattizzo, Bruno, et al.
Publicado: (2021)

Membranous nephropathy after allogeneic hematopoietic stem cell transplantation in a patient with aplastic anemia: a case report.
por: Kim, Kee Won, et al.
Publicado: (2003)

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E., et al.
Publicado: (2018)

Detection and treatment of cerebral toxoplasmosis in an aplastic pediatric post-allogeneic hematopoietic cell transplant patient: a case report
por: Brewer, Danielle, et al.
Publicado: (2021)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Alemtuzumab-induced elimination of HIV-1-infected immune cells
por: Ruxrungtham, Kiat, et al.
Publicado: (2016)

S105: ADDING AZATHIOPRINE/HYDROXYUREA PRECONDITIONING TO ALEMTUZUMAB/TBI CONDITIONING IMPROVES DONOR CHIMERISM IN MATCHED SIBLING DONOR STEM CELL TRANSPLANTATION IN ADULT SICKLE CELL DISEASE PATIENTS
por: Dovern, E, et al.
Publicado: (2022)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center
por: Lloyd, Rebecca, et al.
Publicado: (2020)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Allogeneic peripheral blood stem cell rescue of late graft failure after bone marrow transplantation in patients with aplastic anemia.
por: Chung, Ik-Joo, et al.
Publicado: (2002)

P788: OUTCOME OF SEVERE APLASTIC ANEMIA TREATED WITH ALLOGENIC STEM CELL TRANSPLANTATION COMPARED WITH IMMUNOSUPPRESSIVE THERAPY AS FIRST LINE.
por: Haroon, Alfadil, et al.
Publicado: (2023)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
por: Guan, Yihong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kqd4pg8d8gq6e7vplkto97mkf8